Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by Jkj193741on Apr 21, 2020 5:06pm
176 Views
Post# 30936137

RE:RE:RE:RE:Zenith

RE:RE:RE:RE:ZenithGV I WOLULD HAVE TO STRAIN MY POOR EYES TOO MUCH TO LOOK BACK ON THE TRIAL, BUT DONT YOU RECALL THAT WE HAD A DRUG APPROVED FOR TRIAL BUT THE TRIAL NEVER COMMENCED. ALL WERE SILENT FOR MONTHS THEN WE WERE FINALLY TOLD THAT AN EX EMPLOYEE LAID CLAIM TO THE PATENT FOR THE DRUG, ALL AFTER HUGE EXPENSE AND TRAVAIL. BOTTOM LIME; DM HAS HID HANDS FULL WITH TRYING TO KEEP RVX GOING. WE, THE ZENITH BOARD, OUGHT TO CONSIDER A NEW CEO FOR ITSELF 
, RELEIVING DM OF SOME STRESS SUCH THAT HE COULD DEVOTE FULL TIME TO RVX. LESSON FOR ME: IF WE COULD GO TO TRIL THEN FOR A DRUG WE DID NOT HAVE A VALID I.P. ON; COULD NOT THE SAME SORT OF SLIP REOCCUR UNDER THESE TRYING TIMES? I AM SURE BEAR OR SOME OF THE OTHER OLD TIMERS MAY BE ABLE TO CORRECT MY RECOLLECTION. OF COURS DM WOULD LIKELY HAVE TO RELINQUISH THAT $500 k I THINK HE STILL GETS AS CEO OF ZENITH OR MAYBE CUT IT IN HALF AND HE COULD REMAIN A AN SENIOR OFFICER OR WHATEVER. HE HAS DONE ALL THAT COULD BE EXPECTED TO DATE, BUT MAYBE SOME FRESH BLOOD AT ZENITH MIGHT ENLIVIN THINGS A BIT. AS TOIN V USED TO SAY, " JUST THINKIN A LOUD! NO CRITISM INTENDED!
<< Previous
Bullboard Posts
Next >>